Fundz

Adverum Biotechnologies reported raising $128 Million in an initial SEC Form D filing, from an offering of $128 Million

PRIVATEFeb 21, 2024

Amount Raised

$128 Million

$128 Million sold, per SEC Form D (first sale Feb 7, 2024)

Round Type

Venture

Redwood CityBiotechnologyHealth CareMedicalTherapeutics

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as Adverum Biotechnologies that raised within 45 days of this round, from Fundz verified event records.

  • MAIA Biotechnology raised $2.9M (Seed) on March 11, 2024.
  • Sequana Medical raised $12M on March 22, 2024.
  • Enliven Therapeutics raised $90M on March 21, 2024.
  • AEON Biopharma raised $15M (Convertible Note) on March 21, 2024.
  • Nouscom raised $76M (Series C) on March 21, 2024.
  • Capstan Therapeutics raised $175M (Series B) on March 20, 2024.

Who to call at Adverum Biotechnologies, and when

A new round usually means Adverum Biotechnologies is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Adverum Biotechnologies raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Adverum Biotechnologies, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Adverum Biotechnologies. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Adverum Biotechnologies

Location

Redwood City, California, United States

About

At Adverum, we are driven to establish gene therapy as a new standard of care for debilitating ocular diseases. Adverum aspires to transform the standard of care, preserve long-term vision, and create a profound societal impact around the globe, by advancing gene therapies for highly prevalent ocular diseases. Leveraging the research capabilities of our IVT platform, we design durable medicines that can be administered in the physician’s office, eliminate the need for frequent retinal injections, in an effort to greatly improve accessibility to treatment.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Adverum Biotechnologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contacts1 person is listed at Adverum Biotechnologies. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Adverum Biotechnologies's next move

See what Strategic adds

Adverum Biotechnologies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.